Trellus Health (AIM:TRLS) has requested that its shares be suspended from trading on AIM with effect from 7.30 a.m. today as the board seeks to protect stakeholders amid ongoing funding uncertainty.
The company, a healthcare group that delivers the Trellus Elevate digital platform for managing chronic conditions, said it had reduced monthly cash burn to an average of c. $300k as of March 2026 and had earlier expected its runway to extend into May following a contract renewal and a co-founder loan, the company said in an RNS.
Further cost-saving measures, including additional compensation cuts and renegotiated vendor contracts, have pushed the runway to mid-June 2026 but the board said it has not yet secured long-term funding and that utilisation of the Convertible Loan Note Facility provided by Alumni Capital remains constrained by current market conditions.
Consequently the board has engaged corporate restructuring advisers and is evaluating all options, including the sale of Trellus Health, the company's US subsidiary.
